William Blair Investment Management LLC Cuts Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

William Blair Investment Management LLC reduced its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 42,737 shares of the medical research company’s stock after selling 715 shares during the quarter. William Blair Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $24,839,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. WCM Investment Management LLC lifted its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after buying an additional 2,928 shares during the last quarter. Summa Corp. purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $418,000. S. R. Schill & Associates raised its holdings in Thermo Fisher Scientific by 106.3% during the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 792 shares during the period. Tsfg LLC boosted its holdings in shares of Thermo Fisher Scientific by 8.3% in the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after acquiring an additional 19 shares during the period. Finally, Private Wealth Management Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $110,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Down 0.1 %

Thermo Fisher Scientific stock opened at $555.06 on Thursday. The stock has a market cap of $211.88 billion, a PE ratio of 35.60, a price-to-earnings-growth ratio of 2.59 and a beta of 0.77. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The stock has a fifty day moving average of $566.97 and a 200 day moving average of $564.45. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The business had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Insider Activity

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,430,359.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the sale, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The disclosure for this sale can be found here. Insiders have sold 22,000 shares of company stock worth $12,532,780 in the last three months. Company insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on TMO shares. Evercore ISI reduced their target price on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Deutsche Bank Aktiengesellschaft upped their price target on Thermo Fisher Scientific from $600.00 to $610.00 and gave the company a “buy” rating in a research report on Thursday, April 25th. Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. Five research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $605.63.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.